ReviewArchivos de bronconeumologia2017
Anti-Influenza Treatment: Drugs Currently Used and Under Development.
Review in Archivos de bronconeumologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Porcine Erythrocyte-PRRSV Interactions: Implications for Targeted Nanodrug Delivery.Veterinary sciences · 2026Article
- Attitudes and practices of healthcare professionals in a comprehensive tertiary hospital regarding traditional Chinese medicine for the treatment of influenza.Scientific reports · 2025Article
- Anti-influenza A (H1N1) virus effect of gallic acid through inhibition of virulent protein production and association with autophagy.Food science & nutrition · 2024Article
- The Aqueous Leaf Extract of the Medicinal HerbViruses · 2023Article
- Research progress on antiviral constituents in traditional Chinese medicines and their mechanisms of action.Pharmaceutical biology · 2022Article
- Refined polysaccharide fromFrontiers in immunology · 2022Article
- Enhancing neutralizing activity against influenza H1N1/PR8 by engineering a single-domain VL-M2 specific into a bivalent form.PloS one · 2022Article
- Review
- Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment.Life sciences · 2021Review
- Substantial effect of phytochemical constituents against the pandemic disease influenza-a review.Future journal of pharmaceutical sciences · 2021Review
- Targeting the Host Response: Can We Manipulate Extracellular Matrix Metalloproteinase Activity to Improve Influenza Virus Infection Outcomes?Frontiers in molecular biosciences · 2021Review
- Potential therapeutic and pharmacological strategies for SARS-CoV2.Journal of pharmaceutical investigation · 2021Review
- NaFrontiers in pharmacology · 2021Review
- Dynamic Propagation and Impact of Pandemic Influenza A (2009 H1N1) in Children: A Detailed Review.Current microbiology · 2020Review
- Anti-Influenza Activity of the Ribonuclease Binase: Cellular Targets Detected by Quantitative Proteomics.International journal of molecular sciences · 2020Article
- Effect of eleutheroside B1 on non‑coding RNAs and protein profiles of influenza A virus‑infected A549 cells.International journal of molecular medicine · 2020Article
- Role of Traditional Chinese Medicine in the Management of Viral Pneumonia.Frontiers in pharmacology · 2020Review
- Structural insight into RNA synthesis by influenza D polymerase.Nature microbiology · 2019Article
- Targeting Metalloenzymes for Therapeutic Intervention.Chemical reviews · 2019Review
- Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.Frontiers in microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Influenza is a very common contagious disease that carries significant morbidity and mortality. Treatment with antiviral drugs is available, which if administered early, can reduce the risk of severe complications. However, many virus types develop resistance to those drugs, leading to a notable loss of efficacy. There has been great interest in the development of new drugs to combat this disease. A wide range of drugs has shown anti-influenza activity, but they are not yet available for use in the clinic. Many of these target viral components, which others are aimed at elements in the host cell which participate in the viral cycle. Modulating host components is a strategy which minimizes the development of resistance, since host components are not subject to the genetic variability of the virus. The main disadvantage is the risk of treatment-related side effects. The aim of this review is to describe the main pharmacological agents currently available and new drugs in the pipeline with potential benefit in the treatment of influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.